Akela Pharma signs an exclusive development agreement to develop special oral dosage forms at its PharmaForm subsidiary (CNW Group via Yahoo! Finance) PDF Print

Akela Pharma Inc. , a drug development company focused on developing an inhaled fentanyl product for breakthrough cancer pain and a growth hormone releasing hormone for chronic renal disease, today announced that its wholly owned subsidiary, PharmaForm, has signed a development agreement with an undisclosed global pharmaceutical company, to develop specialized oral dosage forms at its facility ...

read more

 
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.